These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25996638)

  • 1. Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review.
    Douglas MP; Ladabaum U; Pletcher MJ; Marshall DA; Phillips KA
    Genet Med; 2016 Feb; 18(2):111-6. PubMed ID: 25996638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Actionable secondary findings from whole-genome sequencing of 954 East Asians.
    Tang CS; Dattani S; So MT; Cherny SS; Tam PKH; Sham PC; Garcia-Barcelo MM
    Hum Genet; 2018 Jan; 137(1):31-37. PubMed ID: 29128982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.
    Sharma P; Boyers D; Boachie C; Stewart F; Miedzybrodzka Z; Simpson W; Kilonzo M; McNamee P; Mowatt G
    Health Technol Assess; 2012; 16(17):1-266. PubMed ID: 22469073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The burden of pathogenic variants in clinically actionable genes in a founder population.
    Lynch MT; Maloney KA; Pollin TI; Streeten EA; Xu H; ; Shuldiner AR; Van Hout CV; Gonzaga-Jauregui C; Mitchell BD
    Am J Med Genet A; 2021 Nov; 185(11):3476-3484. PubMed ID: 34467620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation.
    Leaviss J; Davis S; Ren S; Hamilton J; Scope A; Booth A; Sutton A; Parry G; Buszewicz M; Moss-Morris R; White P
    Health Technol Assess; 2020 Sep; 24(46):1-490. PubMed ID: 32975190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic Impact and Cost-effectiveness of Whole-Exome Sequencing for Ambulant Children With Suspected Monogenic Conditions.
    Tan TY; Dillon OJ; Stark Z; Schofield D; Alam K; Shrestha R; Chong B; Phelan D; Brett GR; Creed E; Jarmolowicz A; Yap P; Walsh M; Downie L; Amor DJ; Savarirayan R; McGillivray G; Yeung A; Peters H; Robertson SJ; Robinson AJ; Macciocca I; Sadedin S; Bell K; Oshlack A; Georgeson P; Thorne N; Gaff C; White SM
    JAMA Pediatr; 2017 Sep; 171(9):855-862. PubMed ID: 28759686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation.
    Snowsill T; Coelho H; Huxley N; Jones-Hughes T; Briscoe S; Frayling IM; Hyde C
    Health Technol Assess; 2017 Sep; 21(51):1-238. PubMed ID: 28895526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of ACMG secondary findings recommendations for general population screening: a policy statement of the American College of Medical Genetics and Genomics (ACMG).
    ACMG Board of Directors
    Genet Med; 2019 Jul; 21(7):1467-1468. PubMed ID: 31019278
    [No Abstract]   [Full Text] [Related]  

  • 12. The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence.
    Ekpu VU; Brown AK
    Tob Use Insights; 2015; 8():1-35. PubMed ID: 26242225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Medically Actionable Secondary Findings in the 1000 Genomes.
    Olfson E; Cottrell CE; Davidson NO; Gurnett CA; Heusel JW; Stitziel NO; Chen LS; Hartz S; Nagarajan R; Saccone NL; Bierut LJ
    PLoS One; 2015; 10(9):e0135193. PubMed ID: 26332594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
    Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A
    Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic testing and economic evaluations: a systematic review of the literature.
    D'Andrea E; Marzuillo C; Pelone F; De Vito C; Villari P
    Epidemiol Prev; 2015; 39(4 Suppl 1):45-50. PubMed ID: 26499415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic removal of impacted mandibular third molars: a systematic review and economic evaluation.
    Hounsome J; Pilkington G; Mahon J; Boland A; Beale S; Kotas E; Renton T; Dickson R
    Health Technol Assess; 2020 Jun; 24(30):1-116. PubMed ID: 32589125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incremental net benefit of whole genome sequencing for newborns and children with suspected genetic disorders: Systematic review and meta-analysis of cost-effectiveness evidence.
    Nurchis MC; Riccardi MT; Radio FC; Chillemi G; Bertini ES; Tartaglia M; Cicchetti A; Dallapiccola B; Damiani G
    Health Policy; 2022 Apr; 126(4):337-345. PubMed ID: 35317923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Actionable genomic variants in 6045 participants from the Qatar Genome Program.
    Elfatih A; Mifsud B; Syed N; Badii R; Mbarek H; Abbaszadeh F; ; Estivill X
    Hum Mutat; 2021 Aug; ():. PubMed ID: 34428338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy.
    Hockenhull J; Elremeli M; Cherry MG; Mahon J; Lai M; Darroch J; Oyee J; Boland A; Dickson R; Dundar Y; Boyle R
    Health Technol Assess; 2012; 16(12):III-IV, 1-110. PubMed ID: 22409877
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.